Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
 
Online Report Subscribers, Click Here
Pricing and Ordering Information
ClearState

China Senile Dementia Drug Market Report 2008
Report #DHP9005 - March 2009

It is conservatively estimated that there are at least six million Chinese Senile Dementia (SD) patients, a category that includes vascular dementia, Alzheimer’s disease and other types of dementia patients. By the year 2025 there will be approximately 250 million Chinese people aged 60 years or older of which it is forecast that there will be almost 10.1 million senile dementia patients. With the growing number of patients, sales of senile dementia drugs in the Chinese hospital market have risen dramatically since 2003 when the annual growth rate was 4.7% to a growth rate of 20.7% in 2007. This has lead to the market almost doubling in value since 2003 with annual sales of dementia drugs in 2007 of over RMB 6 Billion (approximately USD 1 Billion).

This new report thoroughly analyzes the Chinese dementia drug market. All of the drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitoring system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (China Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou and cover significant percentages of all hospitals in these regions. The comprehensive hospital utilization data of major dementia drugs provides a clear picture of the competitive landscape of the Chinese dementia drug market and the market potential for both products that are already marketed in China or those shortly to be launched in the Chinese marketplace. Market shares for all of the major competitors, including multinational and Chinese pharmaceutical companies and their major dementia products, are presented within this meticulously-researched report.

Ordering Information

Title

 Report# Publication
Date		 List Price

China Senile Dementia Drug Market Report 2008

DHP9005

 March 2009

$8,000
Order Online:
Single User only (Please call for corporate subscription pricing)		   Print + PDF PDF Only

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

 

TABLE OF CONTENTS

Top 20 Pharmaceutical Companies in the Chinese Dementia Drug Market Prelude

 

Chapter I: Overview of Dementia Drugs

Section 1:  Drug Development for Senile Dementia

1. Pathogenesis of Senile Dementia

1.1 Theory of the Abnormal Microtubule Associated Protein (Tau)

1.2 Aβ Toxicity Theories

1.3 Gene Mutation Theory

 

Section 2:  Classification of Senile Dementia Drugs

1. Cholinergic Receptor Agonist (CRA)

1.1 M Type of Cholinergic Receptor Agonist

1.2 Nicotinic Receptor Agonist

2. Cholinesterase Inhibitor

2.1 Donepezil

2.2 Rivastigmine

2.3 Galantamin

2.4 Huperzine A

2.5 Ganstigmine

2.6 Physostiamine

2.7 Phenserine and Tolserine

3. Drugs Acting on NMDA Receptor

4. Amyloid β-protein (Aβ) Forming Inhibitor

4.1 Cholesterol Reducing Drugs

4.2 Nonsteroidal Anti-inflammatory Drugs (NSAID)

4.3 Estrogen4.4 Metal Chelator

5. Antioxidant

6. Calcium Antagonist

7. Nerve Growth Factor (NGF) and Nerve Stem

    Cells (NSCs)

8. Aβ Vaccine

9. Gene Therapy

10. Prospects

 

Chapter II: Global Dementia Drug Market

 

Chapter III: The Chinese Dementia Drug Market

Section 1:  The Chinese Market of Senile Dementia Drugs

Section 2:  Market Shares of Top Dementia Drugs

Section 3:  Market Shares of Top Manufacturers

Section 4:  Growth Rates of Top Senile Dementia Drugs

Section 5:  Market Potential of Brand Dementia Drugs

Section 6:  Top 10 Brand Dementia Drugs in China 2006-2007

1. Market Shares and Sizes of Ginkgo Biloba Extract by

    Manufacturers 2005-2007

2. Market Shares and Sizes of Ganglioside by

    Manufacturers 2005-2007

3. Market Shares and Sizes of Oxiracetam by

    Manufacturers 2005-2007

4. Market Shares and Sizes of Breviscapine by

    Manufacturers 2005-2007

5. Market Shares and Sizes of Edaravone by

    Manufacturers 2005-2007

6. Market Shares and Sizes of Vinpocetine by

    Manufacturers 2005-2007

7. Market Shares and Sizes of Meclofenoxate

    (Luzhixing) by Manufacturers 2005-2007

8. Market Shares and Sizes of Nicergoline by

    Manufacturers 2005-2007

9. Market Shares and Sizes of Rat Nerve Growth Factor

    (rNGF) by Manufacturers 2005-2007

10. Market Shares and Sizes of Almitrine/raubasine by

      Manufacturers 2005-2007

 

Chapter IV: Brand Names, Generic Names, Formulas and Manufacturers of Dementia Drugs in China

Section 1:  Brand Names, Generic Names, Formulas and Manufacturers of Allergy Drugs in China

Section 2:  Brand Names, Generic Names, Formulas, Manufacturers and Approval Time of Newly Approved Dementia Drugs

 

Chapter V: Dementia Drugs on the National Basic Healthcare Insurance List

Section 1:  Names, Formulas, Packages and Retail Prices (by Regions) of Dementia Drugs

Section 2:  Dementia Drugs (Chemical Drugs) on the National Basic Healthcare Insurance List

Section 3:  Dementia Drugs (TCMs) on the National Basic Healthcare Insurance List

 

Chapter VI: Overview of R&D for Dementia Drugs

Section 1:  Amyloid-β Protein as Immunotherapy for Alzheimer’s Disease

1. Immunotherapy with Amyloid-β Protein

1.1 Passive Immunotherapy

1.2 Active Immunotherapy

1.3 Gene Immunotherapy

1.4 Clinic trials for Aβ immunotherapy

2. Mechanism of Aβ Immunotherapy

3. Adverse Reactions from Aβ Immunotherapy

4. Prospects

 

Section 2:  R&D of Traditional Chinese Medicines for the Treatment of Alzheimer’s Disease

1. Ginkgo biloba L and Ginkgo Active Ingredients

2. Huperzia serrata Thunb and Huperzine Compounds

3. Salvia miltiorrhiza Bung and Salvia miltiorrhiza Active

    Ingredients

4. Panax ginseng C.A.Mayer and Panaxoside

5. Other Chinese Herb Monomers and Active

    Ingredients

6. Compound TCM

 

Exhibits

Table 1:     Marketed Drugs for the Treatment of Alzheimer’s Disease

Table 2:     Drugs for Alzheimer’s Disease in Phase III Studies

Table 3:     Market Shares of Top 20 Dementia Drugs in China 2005-2007

Table 4:     Market Sizes of Top 20 Dementia Drugs in China 2005-2007

Table 5:     Market Shares of Top 20 Pharmaceutical Companies in the Chinese Dementia Drug Market 2005-2007

Table 6:     Market Sizes of Top 20 Pharmaceutical Companies in the Chinese Dementia Drug Market 2005-2007

Table 7:     Annual and Compound Annual Growth Rates of Top 20 Dementia Drugs in the Chinese Market 2005-2007

Table 8:     Market Shares of Ginkgo Biloba Extract by Manufacturers 2005-2007

Table 9:     Market Sizes of Ginkgo Biloba Extract by Manufacturers 2005-2007

Table 10:   Market Shares of Ganglioside by Manufacturers 2005-2007

Table 11:   Market Sizes of Ganglioside by Manufacturers 2005-2007

Table 12:   Market Shares of Oxiracetam by Manufacturers 2005-2007

Table 13:   Market Sizes of Oxiracetam by Manufacturers 2005-2007

Table 14:   Market Shares of Herba Erigerontis by Manufacturers 2005-2007

Table 15:   Market Sizes of Herba Erigerontis by Manufacturers 2005-2007

Table 16:   Market Shares of Vinpocetine by Manufacturers 2005-2007

Table 17:   Market Sizes of Vinpocetine by Manufacturers 2005-2007

Table 18:   Market Shares of Meclofenoxate by Manufacturers 2005-2007

Table 19:   Market Sizes of Meclofenoxate by Manufacturers 2005-2007

Table 20:   Market Shares of Nicergoline by Manufacturers 2005-2007

Table 21:   Market Sizes of Nicergoline by Manufacturers 2005-2007

Table 22:   Market Shares of rNGF by Manufacturers 2005-2007

Table 23:   Market Sizes of rNGF by Manufacturers 2005-2007

Table 24:   Brand Names, Generic Names, Formulas and Manufacturers of Allergy Drugs in China

Table 25:   Brand Names, Generic Names, Formulas and Manufacturers of Dementia Drugs in China

Table 26:   Names, Formulas, Packages and Retail Prices of Dementia Drugs in China

Table 27:   Chemical Dementia Drugs on the National Basic Healthcare Insurance List

Table 28:   TCM Dementia Drugs on the National Basic Healthcare Insurance List

 

Figure 1:    Sales and Market Growth of Chinese Dementia Drugs 2003-2007

Figure 2:    Future Potential of Top Anti-senile Dementia Drugs in China

Figure 3:    Top 10 Branded Dementia Drugs in 2006

Figure 4:    Top 10 Branded Dementia Drugs in 2007

 

Top 20 Pharmaceutical Companies in the Chinese Dementia Drug Market (with at least 1.86% of the total dementia drug market in 2007)

 

·   Harbin Sanlian

·   Beijing Shuanghe

·   Guangdong Shixin

·   Guizhou Yibai

·   Hainan Tongyong Sanyang

·   Heilongjiang Feixia

·   Heilongjiang Zhenbaodao

·   Henan Lingrui

·   Kunming Longjin

·   Nanjing Xiansheng Dongyuan

·   Shandong Qilu

·   Shanghai Xinxianfeng

·   Shanxi Pude

·   Shanxi Wanrong

·   Shijiazhuang Shenwei

·   TRB Pharma S.A.

·   Willmar Schwabe

·   Yangtze River

·   Yunnan Shengwugu Dengzhanhua (Herba Erigerontis)

·   Hunan Jianlang

 

 

Draco Healthcare Consulting is the leader in the China-focused healthcare consulting business. They serve leading pharmaceutical and biotech companies both inside and outside of China to make better medicines for China. www.dracohealthcare.com

 

To order reports or obtain information about special pre-publication offers from within the U.S., contact sales@medtechinsight.com. From outside the U.S., contact internationalsales@medtechinsight.com. You can also call 1.949.453.0071 (or toll-free within the U.S. at 1.888.290.2225) or fax 1.949.453.0072.

 

The Newsletter | The Principals | Reports | Conferences | Physician Surveys | Consulting | Contact Us | Home